Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
11Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Inovio Pharmaceuticals, Inc. (INO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
16Total relationships
4Distinct source URLs
9High confidence
0.799Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Inovio Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
OPPENHEIMER-CO-INC
OPPENHEIMER-CO-INC
92%
The Company notified Oppenheimer & Co. Inc. (the “Sales Agent”) that it was suspending and terminating the prospectus, dated August 13, 2024
Inovio Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
APOLLOBIO
APOLLOBIO
92%
During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.
GOVERNMENT
GOVERNMENT
90%
A small number of licensing partners and government contracts have accounted for a substantial portion of our revenue.
LICENSING-PARTNERS
LICENSING-PARTNERS
90%
A small number of licensing partners and government contracts have accounted for a substantial portion of our revenue.
OPPENHEIMER-CO-INC
OPPENHEIMER-CO-INC
90%
the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, through the Sales Agent
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from INO graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from INO graph: Reciprocal relationship from SNYNF …
SNYNF
Sanofi
72%
f our proprietary device by the medical community; • the prevalence and severity of any actual or perceived adverse side effects; • limitations or warnings contained in a product's FDA-approved label…
Reciprocal relationship from VXRT graph: irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, produ…
AKESO-APOLLOBIO-CORPORATION
AKESO-APOLLOBIO-CORPORATION
62%
Item 1. Financial Statements 1 INOVIO PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2026 December 31, 2025 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 26,27…
APOLLOBIO-CORPORATION
APOLLOBIO-CORPORATION
62%
HSIL, but announced in 2023 that we were ceasing development for this indication in the United States. However, our collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of…
COLLABORATIVE-AGREEMENTS-APOLLOBIO-CORPORATION
COLLABORATIVE-AGREEMENTS-APOLLOBIO-CORPORATION
62%
rrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and developmen…
OPERATIONS-INOVIO-PHARMACEUTICALS-INC
OPERATIONS-INOVIO-PHARMACEUTICALS-INC
62%
Item 1. Financial Statements 1 INOVIO PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2026 December 31, 2025 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 26,27…
Inovio Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
INO-DEBT-10296
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
INO-DEBT
Debt stack $62.8M
90%
Market cache reports total debt of $62.8M.
INO-DEBT-10295
Warrants outstanding: 681625
90%
xbrl warrant detail from xbrl 2025-12-31.
Inovio Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Inovio Pharmaceuticals, Inc..
Inovio Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
INO-OWNER-FMR-LLC
FMR LLC
90%
13F overlay lists FMR LLC as top holder; 101 tracked holders.
Inovio Pharmaceuticals, Inc. Extended Supply Chain Network
